Back to mobile site

Valeant Pharma (VRX) Adds ValueAct's Morfit as Director

October 26, 2015 6:13 AM EDT Send to a Friend
Valeant Pharma (NYSE: VRX) announced the addition of G. Mason Morfit, President of ValueAct Capital, to its board of directors ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login